Kalaris Therapeutics (NASDAQ:KLRS) Trading Up 0.9% - Here's What Happened

Key Points

• Kalaris Therapeutics (NASDAQ:KLRS) saw its shares increase by 0.9%, with a trading range between $4.64 and $4.74, despite significantly lower trading volume compared to the average.
• Analysts have mixed views on Kalaris, with one rating it a strong buy and another assigning a hold rating, leading to an average price target of $3.00.
• The company reported a quarterly loss, with an EPS of ($0.61), falling short of the consensus estimate by $0.10.

Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report)'s share price traded up 0.9% during trading on Tuesday . The stock traded as high as $4.74 and last traded at $4.68. 84,795 shares were traded during mid-day trading, a decline of 87% from the average session volume of 673,934 shares. The stock had previously closed at $4.64.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Raymond James Financial assumed coverage on Kalaris Therapeutics in a research report on Tuesday, September 2nd. They issued a "strong-buy" rating on the stock. Wall Street Zen upgraded Kalaris Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, June 17th. Finally, Piper Sandler set a $3.00 price objective on Kalaris Therapeutics and gave the company a "neutral" rating in a research report on Wednesday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, Kalaris Therapeutics currently has an average rating of "Buy" and a consensus target price of $3.00.

Kalaris Therapeutics Price Performance

The business has a 50 day moving average of $2.99.

Kalaris Therapeutics (NASDAQ:KLRS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.10).

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Kalaris Therapeutics stock. XTX Topco Ltd bought a new stake in shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 24,234 shares of the company's stock, valued at approximately $65,000. XTX Topco Ltd owned about 0.13% of Kalaris Therapeutics as of its most recent filing with the Securities & Exchange Commission. 66.05% of the stock is currently owned by institutional investors.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.